Sawsan Rashdan: Phase II Trial on Osimertinib and Radiotherapy for NSCLC
Sawsan Rashdan, Associate Professor at UT Southwestern Medical Center, shared on LinkedIn:
“Thrilled to share that our investigator-initiated Phase II multi-center trial, where I served as the Primary Investigator, studying osimertinib + consolidative radiotherapy in advanced EGFR-mutated NSCLC has just been published in eClinicalMedicine, The Lancet’s journal!
This collaborative effort between UT Southwestern Medical Center and City of Hope provides important new insights into optimizing first-line treatment strategies for patients with EGFR-mutated non-small cell lung cancer.
I am deeply grateful to my mentor, Dr. David Gerber, whose guidance and support were invaluable throughout this journey. Grateful as well to my colleagues, collaborators, and patients who made this milestone possible.”
More posts featuring Sawsan Rashdan.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023